BioLineRx Ltd.

DB:YP2A Stock Report

Market Cap: €23.5m

BioLineRx Management

Management criteria checks 2/4

BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 8.08 years. total yearly compensation is $952.00K, comprised of 29.4% salary and 70.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth €3.37K. The average tenure of the management team and the board of directors is 7.8 years and 2.9 years respectively.

Key information

Phil Serlin

Chief executive officer

US$952.0k

Total compensation

CEO salary percentage29.4%
CEO tenure8.1yrs
CEO ownership0.01%
Management average tenure7.8yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Phil Serlin's remuneration changed compared to BioLineRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$49m

Dec 31 2023US$952kUS$280k

-US$61m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$32m

Dec 31 2022US$1mUS$297k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$22m

Dec 31 2021US$903kUS$290k

-US$27m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$34m

Dec 31 2020US$958kUS$250k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019US$678kUS$256k

-US$25m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$846kUS$254k

-US$23m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$26m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$612kUS$240k

-US$24m

Compensation vs Market: Phil's total compensation ($USD952.00K) is above average for companies of similar size in the German market ($USD471.55K).

Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.

CEO

Phil Serlin (64 yo)

8.1yrs

Tenure

US$952,000

Compensation

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leadership Team

NamePositionTenureCompensationOwnership
Philip Serlin
Chief Executive Officer8.1yrsUS$952.00k0.014%
€ 3.4k
Mali Zeevi
Chief Financial Officer8.1yrsUS$443.00k0.027%
€ 6.4k
Ella Sorani
Chief Development Officer7.8yrsUS$520.00k0.0055%
€ 1.3k
Holly May
President of BioLineRx USA2.4yrsUS$1.01mno data
John Lacey
Head of Corporate Communications & Investor Relationsno datano datano data
Tsipi Keren-Lehrer
Head of BD & Strategic Advisor5.3yrsno datano data
Raziel Fried
Treasurer & Budgetary Control Directorno datano datano data

7.8yrs

Average Tenure

59yo

Average Age

Experienced Management: YP2A's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Aharon Schwartz
Chairman of the Board20.8yrsno data0.31%
€ 72.6k
Sandra Panem
Director10.8yrsno datano data
Avraham Molcho
Independent External Director14.3yrsUS$26.55kno data
Raphael Hofstein
Director21.8yrsUS$140.92kno data
Ronald Levy
Member of Immuno-Oncology Scientific Advisory Board2.9yrsno datano data
Rami Dar
Independent External Director2.3yrsno datano data
Gal Cohen
Independent Directorless than a yearno datano data
Barbar-Jean Bormann-Kennedy
Director11.3yrsno datano data
Jon Marc Wigginton
Member of Immuno-Oncology Scientific Advisory Board2.9yrsno datano data
Ignacio Melero Bermejo
Member of Immuno-Oncology Scientific Advisory Board2.9yrsno datano data
Aurelien Marabelle
Member of Immuno-Oncology Scientific Advisory Board2.9yrsno datano data
Shaoyu Yan
Directorless than a yearno datano data

2.9yrs

Average Tenure

66yo

Average Age

Experienced Board: YP2A's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.